Last reviewed · How we verify
Alkaline citrate
Alkaline citrate raises urinary pH to reduce stone formation and dissolution of existing calculi.
Alkaline citrate raises urinary pH to reduce stone formation and dissolution of existing calculi. Used for Prevention and treatment of recurrent kidney stones (nephrolithiasis), Uric acid stone disease.
At a glance
| Generic name | Alkaline citrate |
|---|---|
| Also known as | no brand names, Shol's solution versus placebo solution (NaCl 0.9 %) |
| Sponsor | University of Cologne |
| Drug class | Urinary alkalinizing agent |
| Modality | Small molecule |
| Therapeutic area | Urology / Nephrology |
| Phase | Phase 3 |
Mechanism of action
Alkaline citrate works by increasing urinary alkalinity, which decreases the solubility of uric acid and calcium oxalate crystals, thereby preventing kidney stone formation and promoting dissolution of existing stones. Citrate also acts as a stone inhibitor by binding to calcium and reducing crystal aggregation. This mechanism is particularly effective for uric acid stones and calcium oxalate nephrolithiasis.
Approved indications
- Prevention and treatment of recurrent kidney stones (nephrolithiasis)
- Uric acid stone disease
Common side effects
- Gastrointestinal upset (nausea, diarrhea)
- Hyperkalemia
- Metabolic alkalosis
Key clinical trials
- The Effects of Magnesium (Mg) Supplement and Alternate Maxillary Expansion and Constriction (Alt-RAMEC) in Patient With Transverse Maxillary Deficiency (TMD) (NA)
- Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation (NA)
- Magnesium Citrate Supplementation on Hand Grip Strength (NA)
- Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants (NA)
- The Effect of Oral Vitamin D Supplements on Fusion Outcome in Patients Receiving Elective Lumbar Spinal Fusion (NA)
- Efficacy of Vitamin D Supplementation in Bariatric Surgery Patients (NA)
- Effect of Vitamin D Supplement in Induction of Ovulation in Overweight Women With Polycystic Ovary Syndrome (PHASE3)
- Bioavailability of Magnesium Supplements (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |